JP2013504603A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504603A5
JP2013504603A5 JP2012529062A JP2012529062A JP2013504603A5 JP 2013504603 A5 JP2013504603 A5 JP 2013504603A5 JP 2012529062 A JP2012529062 A JP 2012529062A JP 2012529062 A JP2012529062 A JP 2012529062A JP 2013504603 A5 JP2013504603 A5 JP 2013504603A5
Authority
JP
Japan
Prior art keywords
csf
antibody
cns
use according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012529062A
Other languages
English (en)
Japanese (ja)
Other versions
JP5785550B2 (ja
JP2013504603A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2010/001191 external-priority patent/WO2011032204A1/en
Publication of JP2013504603A publication Critical patent/JP2013504603A/ja
Publication of JP2013504603A5 publication Critical patent/JP2013504603A5/ja
Application granted granted Critical
Publication of JP5785550B2 publication Critical patent/JP5785550B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012529062A 2009-09-15 2010-09-14 神経疾患の処置方法 Expired - Fee Related JP5785550B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24250309P 2009-09-15 2009-09-15
US61/242,503 2009-09-15
PCT/AU2010/001191 WO2011032204A1 (en) 2009-09-15 2010-09-14 Treatment of neurological conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015109380A Division JP2015187135A (ja) 2009-09-15 2015-05-29 神経疾患の処置方法

Publications (3)

Publication Number Publication Date
JP2013504603A JP2013504603A (ja) 2013-02-07
JP2013504603A5 true JP2013504603A5 (https=) 2013-10-10
JP5785550B2 JP5785550B2 (ja) 2015-09-30

Family

ID=43757935

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012529062A Expired - Fee Related JP5785550B2 (ja) 2009-09-15 2010-09-14 神経疾患の処置方法
JP2015109380A Pending JP2015187135A (ja) 2009-09-15 2015-05-29 神経疾患の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015109380A Pending JP2015187135A (ja) 2009-09-15 2015-05-29 神経疾患の処置方法

Country Status (11)

Country Link
US (2) US9364534B2 (https=)
EP (1) EP2477656B1 (https=)
JP (2) JP5785550B2 (https=)
KR (1) KR101750426B1 (https=)
CN (1) CN102630167B (https=)
AU (1) AU2010295223B2 (https=)
CA (1) CA2773552C (https=)
DK (1) DK2477656T3 (https=)
ES (1) ES2623802T3 (https=)
PL (1) PL2477656T3 (https=)
WO (1) WO2011032204A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117092A1 (en) * 2009-10-20 2011-05-19 The Regents Of The University Of Michigan Compositions and methods for inhibiting g-csfr
JP6187777B2 (ja) * 2011-06-13 2017-08-30 シーエスエル、リミテッド G−csfrに対する抗体およびその使用
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
WO2019226550A1 (en) * 2018-05-21 2019-11-28 CHS Pharma Inc. Granulocyte colony-stimulating factor (gcsf) gene therapy for treating neurological diseases
CN113272326B (zh) * 2018-12-04 2024-09-27 Csl创新私人有限公司 治疗嗜中性病症的方法
KR20260036321A (ko) 2023-07-05 2026-03-16 씨에스엘 이노베이션 피티와이 엘티디 겸상적혈구병의 합병증을 치료하거나 예방하는 방법
WO2025217678A1 (en) * 2024-04-15 2025-10-23 CSL Innovation Pty Ltd Methods of treating or delaying progression or hindering development of a neutrophil-associated condition

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0966484A4 (en) * 1996-05-07 2002-04-17 Millennium Pharm Inc NEUROTACTIN AND APPLICATIONS THEREOF
JP2003525243A (ja) * 2000-02-28 2003-08-26 ザ ユニバーシティ オブ ブリティッシュ コロンビア 炎症性疾患の治療のための組成物及び方法
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
WO2002078643A2 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US20060093604A1 (en) * 2002-08-23 2006-05-04 The Walter And Eliza Hall Institute Of Medical Research Method of treatment and prophylaxis
JP4638876B2 (ja) * 2003-05-23 2011-02-23 ワイス Gitrリガンド及びgitrリガンド関連分子及び抗体及びその使用
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007271163B2 (en) * 2006-07-06 2012-08-23 Merck Serono Sa CSF3R polypeptides and uses thereof
EP2526959B1 (en) 2006-08-11 2017-08-02 CSL Limited Treatment of pulmonary disease conditions
WO2008125903A2 (en) 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response

Similar Documents

Publication Publication Date Title
JP2013504603A5 (https=)
Yang et al. CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications
JP7395483B2 (ja) mRNAの細胞内送達のためのペプチドおよびナノ粒子
JP7579589B2 (ja) Ranタンパク質関連神経学的疾患を処置するための方法
JP2021525248A5 (https=)
US20180010132A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP2021529780A (ja) Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
US20170283807A1 (en) Compositions and methods for diagnosis and treatment of prostate cancer
JP2013537418A5 (https=)
JP2014076062A5 (https=)
JP2017113019A5 (https=)
JP2012067116A5 (https=)
US20250295809A1 (en) Compositions and methods for the treatment of her2 positive cancer
CN113677706B (zh) 肝毒性的治疗
TWI500629B (zh) 介白素-6抗體及其用途
JP2010500291A5 (https=)
CN119343142A (zh) 治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法
JP2015522264A5 (https=)
AU2018314236B2 (en) RNA aptamers against transferrin receptor (TfR)
JP2012505657A5 (https=)
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
JP2021514003A5 (https=)
JP2020511493A (ja) セマフォリン−4d抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法
JP2021520393A5 (https=)
JP2022533287A (ja) Nlrp活性に関連する状態を処置するための化合物及び組成物